Cholinesterase inhibitors, such as pyridostigmine, are essential in the management of MG by increasing acetylcholine availability at NMJs [34], however they also elevate neurotransmitter levels in smooth muscle synapses including the bladder [35]. Here, BCHE is linked to myasthenia gravis.